Emles at Home ETF Aktie - LIV

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

15,725

Gebot

Fragen

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

15,725

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Emles Advisors Announces Closure of Six Funds

Emles Advisors Announces Closure of Six Funds PR Newswire NEW YORK, Sept. 16, 2022 NEW YORK, Sept. 16, 2022 /PRNewswire/ -- Due to the inability...

Samaritan to Initiate Phase III Clinical Trial in Europe to Accelerate Development Timeline of Its HIV Oral Entry Inhibitor SP0

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Trial Designed to Tackle HIV Drug Resistance (One or More of a Patient's Current HIV Drug...

Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor in Phase II 10-Day HIV Monotherapy Trial

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group ? -- Dose...

Samaritan Files Provisional Patent to Support Promising New Type of Anti-cholesterol Drug SP-1000 and Cover Additional Claims;

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Clears Clogged Arteries ? -- Raises HDL ? -- Reduces CK Enzyme Marker: Suggesting It...

Samaritan Starts Enrolling for Its PII Stage 2 (28 Day Monotherapy) Study of ''Oral'' Entry Inhibitor SP-01A

Samaritan Pharmaceuticals (AMEX:LIV): ? -- Completed Phase II Stage 1 (10 Day Monotherapy) ? -- Expect to Report Stage I Preliminary Results...

SIS Foundation Driven to Drive Bio Future Bus So Kids Can Speed up Science Innovation; Only 17% of US Students Graduate with Sc

The Samaritan Foundation and Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today on National DNA day, it...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SS1ARadius Recycling Inc	26,20 € (107,94%)	918
9960Renergen Limited	0,354 € (37,21%)	32,4k
PTCAPHarol SGPS SA	0,0896 € (29,11%)	6,38k
C0MCCS Abwicklungs AG	0,10 € (29,03%)	7,14k
M0YNMynaric AG	1,11 € (25,85%)	70,59k
E3O1Nexoptic Technology Corp	0,0065 € (-35,00%)	257
36GGBM Resources Limited	0,0035 € (-30,00%)	18,85k
27N0Cannovum Cannabis AG	0,202 € (-27,86%)	527
K1SNKlondike Silver Corporation	0,011 € (-26,67%)	80k
L7C2Windfall Geotek Inc	0,0085 € (-26,09%)	34,2k
D7GNel ASA	0,2592 € (-6,93%)	3,92M
DRHDroneShield Limited	0,637 € (10,40%)	1,38M
TKAThyssenkrupp AG	8,448 € (-2,85%)	649,16k
RQ0DWave Quantum Inc	6,686 € (5,23%)	563,62k
M11First Graphene Limited	0,0306 € (15,91%)	288k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Emles at Home ETF (LIV)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

LIV Neueste Nachrichten

Emles Advisors Announces Closure of Six Funds

Samaritan to Initiate Phase III Clinical Trial in Europe to Accelerate Development Timeline of Its HIV Oral Entry Inhibitor SP0

Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor in Phase II 10-Day HIV Monotherapy Trial

Samaritan Files Provisional Patent to Support Promising New Type of Anti-cholesterol Drug SP-1000 and Cover Additional Claims;

Samaritan Starts Enrolling for Its PII Stage 2 (28 Day Monotherapy) Study of ''Oral'' Entry Inhibitor SP-01A

SIS Foundation Driven to Drive Bio Future Bus So Kids Can Speed up Science Innovation; Only 17% of US Students Graduate with Sc

Bio 2006 Analysts Predict Small-Cap Biotechs to Outperform Large-Caps This Year

LIV to Host Annual Shareholders Meeting

Samaritan's Marketing Authorization Application For Amphocil Approved in Greece

Samaritan to Present Its Drugs and Diagnostics for Partnering at BIO 2006 Annual International Conference

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Emles at Home ETF (LIV) Börsenkurse

Emles at Home ETF (LIV)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

LIV Neueste Nachrichten

Emles Advisors Announces Closure of Six Funds

Samaritan to Initiate Phase III Clinical Trial in Europe to Accelerate Development Timeline of Its HIV Oral Entry Inhibitor SP0

Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor in Phase II 10-Day HIV Monotherapy Trial

Samaritan Files Provisional Patent to Support Promising New Type of Anti-cholesterol Drug SP-1000 and Cover Additional Claims;

Samaritan Starts Enrolling for Its PII Stage 2 (28 Day Monotherapy) Study of ''Oral'' Entry Inhibitor SP-01A

SIS Foundation Driven to Drive Bio Future Bus So Kids Can Speed up Science Innovation; Only 17% of US Students Graduate with Sc

Bio 2006 Analysts Predict Small-Cap Biotechs to Outperform Large-Caps This Year

LIV to Host Annual Shareholders Meeting

Samaritan's Marketing Authorization Application For Amphocil Approved in Greece

Samaritan to Present Its Drugs and Diagnostics for Partnering at BIO 2006 Annual International Conference

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP